People living with diabetes might soon have better access to care thanks to an unlikely source: the Internal Revenue Service.
Sandeep Jauhar’s grandfather was sitting down to lunch with family when he crumpled to the floor. Jeff Kwitowski’s father was on a routine bike ride. Cat Davis Ahmed’s father was enjoying a game of tennis. And Florence Champagne was in an office building when she dropped to her knees, gasping for air and praying for her life.
A new white paper from the Congressional Diabetes Caucus reinforces what patients and advocates know all too well — the insulin pricing system is too complicated, the negotiations are too secretive and the cost for patients is too high.
The rising price of insulin has created a multibillion-dollar business for the pharmaceutical oligopoly that controls the market — and a deep sense of anger and fear among people who need the drug to stay alive.
Americans pay more for prescription drugs than any country in the world, and the pharmaceutical industry earns billions in profits each year.
Diabetes is becoming more common. But access to appropriate care for people living with diabetes? Not so much. So explains a new white paper from the Institute for Patient Access.
Children with diabetes face a lifetime of challenges. However, if insurers continue to exclude more and more diabetes-related medications and supplies from coverage, children with diabetes and their families could be saddled with a lifetime of exorbitant out-of-pocket costs as well.
This guide was developed in cooperation with the Diabetes Patient Advocacy Coalition, JDRF, and the diaTribe Foundation, and is made available free of charge thanks to financial support from Sanofi.
In short, healthcare insurers – not healthcare professionals – are making critical decisions about which medications and medical devices will be made available.